|
|
|
|
Late-stage sterile injectable manufacturing demands carefully balancing compliance, capacity, and operational complexity. Early investment in validated systems and processes can help streamline scale-up efforts and support a successful launch.
|
|
|
|
|
Complex sterile injectables need more than fill-finish capacity. Integrating formulation development, analytical expertise, and aseptic filling capabilities helps reduce risk, preserve critical data continuity, streamline technology transfer, and accelerate the path to commercialization.
|
|
|
|
|
Annex 1 has redefined expectations for sterile drug manufacturing, elevating contamination control and risk management from operational considerations to strategic imperatives. For sponsors, compliance is a critical lever for reducing risk, safeguarding value, and maintaining momentum from clinical development through commercialization.
|
|
|
|
|
Though there are two dominant routes for gathering data for an analytical panel—conducting testing at a CDMO with in-house equipment or transporting product samples to analytical testing vendors—the in-house model yields reliable advantages in terms of speed, quality oversight, and program confidence.
|
|
|
|
|
|
|
Advanced automated filling lines and integrated development services streamline production, ensuring process integrity and faster timelines from early formulation to commercial supply.
|
|
|
|
|
A U.S.-based sterile injectable CDMO delivering scalable small and large molecule manufacturing, supported by advanced aseptic technologies, integrated quality systems, and commercial-ready capabilities.
|
|
|
|
|
|
|
